← Evidence library

BIB_331

Helgadottir H, Hansson J et al. (Karolinska + Swedish multicentre). NEO-MEL: Neoadjuvant immunotherapy in resectable stage III/IV cutaneous melanoma — Swedish retrospective real-world study. Eur J Cancer June 2025. PMID 40456667. Key finding: neoadjuvant PD-1 ± CTLA-4 inhibitor superior to adjuvant PD-1 inhibitor in real-world Swedish population. Real-world replication of NADINA + PRADO. [Tasks: 17, 18, 19b] Tier: 2 (real-world replication) Grade: B Retrieved: 2026-05-15

Evidence grade

B

Tier

2 (real-world replication)

Cited by tasks

17, 18, 19b

Identifiers

PMID:40456667

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_331/findings.md (research corpus). This page is a short context summary — not individualised medical advice.